Treatment of streptozotocin diabetes with di-isopropylammonium dichloroacetate (DIPA).
D000085:Acetates / Q000008:administration & dosage / Q000627:therapeutic use; D000284:Administration, Oral; D000818:Animals; D001786:Blood Glucose; D003920:Diabetes Mellitus / Q000139:chemically induced / Q000188:drug therapy*; D016883:Diabetic Ketoacidosis / Q000188:drug therapy; D004341:Drug Evaluation; D005947:Glucose / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007408:Intestinal Absorption / Q000187:drug effects; D007583:Jejunum / Q000378:metabolism; D008297:Male; D010629:Phenformin / Q000494:pharmacology; D011437:Propylamines / Q000008:administration & dosage / Q000627:therapeutic use; D000644:Quaternary Ammonium Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D013311:Streptozocin
D000085:Acetates; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D011437:Propylamines; D000644:Quaternary Ammonium Compounds; D013311:Streptozocin; D010629:Phenformin; D005947:Glucose